The present study investigated the effect of monocrotophos, a commonly used organophosphate pesticide exposure in the kidney tissues of the swiss albino mice. Monocrotophos was administered at the sub-lethal doses of 1.25mg/kg, 2.5 mg/kg and 5.0 mg/kg body weight for 24 hr. Monocrotophos toxicity generated oxidative stress in the mice as evidenced by significant decrease in the activities of glutathione, superoxide dismutase and catalase enzymes. The exposure increased the lipid peroxidation and protein oxidation in a dose dependent manner. Oxidative stress generation also elicited cytotoxic effects on the mice kidney which were supported by the histopathological changes like degeneration in glomerulus, bowmen’s capsule and tubules, hemorrhage, mononuclear cell infiltration, tubular cast and congested blood vessels in a dose-dependent manner. In conclusion, the study indicated that monocrotophos exposure at various doses induces significant deleterious health effects in mice kidney tissues via oxidative stress generation.
Cite as: Devi, S., Singh, J., Kumar, V., & Malik, V. (2019). Monocrotophos induced Biochemical and Histopathological alterations in the Kidney tissues of Mice. Chemical Biology Letters, 6(2), 39-45.
Selected novel β-lactam and thiazolidinone derivatives have been synthesized by the reaction of 4-methyl-1H-isochromen-1-one with 1,1-biphenyl-4,4-diamine, followed by the reaction with substituted benzaldehyde and further by the reaction with chloroacetyl chloride (for β-lactam type) and with thioglycolic acid (for thiazolidinone type) respectively . All the compounds were characterised by 1H NMR, IR and mass spectroscopy. These compounds were screened for in-vitro antimicrobial activity against Staphylococus aureus, E. coli, Pseudomonas aeruginosa strain. Some compounds have shown very good efficacy against antibacterial strain.
Cite as: Bhatt, A., Srivastava, K., Kant, R., & Lakhmani, D. (2019). Synthesis of novel β-lactam and thiazolidinone compounds derived from 4-methyl-1H-isochromen-1-one and their antibacterial activity. Chemical Biology Letters, 6(2), 46-54.
Information for Authors for submitting articles to International Biomedical Frontiers Journal
The Authors need to submit a single file containing all the details
as described below. The supplementary data files should be submitted as a
separate file. A cover letter and graphical abstract should be
submitted along with manuscript as details provided below.
Authors should supply a cover letter indicating rational of their
work. Cover letter should also have details of at least three reviewers
(with email). Cover letter should be provided on the first step of
submission in “Comments for Editor’ box.
Manuscript should include Title, Author (s), Affiliation (complete name of institutions), Abstract, 5 Keywords, (other sections like Introduction, Results and discussion, conclusion, experimental procedures in the main body text of manuscript could be used for full paper article), acknowledgment and references in the listed order. Short communications need not to be arranged in different sections.
The journal accept all type of citation styles. Authors may use any of the available numbered style, but are highly encouraged to use ‘Citation Manager’ program (mendeley etc.) for citation of references. The editorial office will format the references in required format.
References should be formatted as shown for articles,1 theses,2 books,3,4 and patents,5
1. R. Ping, M. Laura, P.S. Mario. Title of the journal article should be included here. Int. Lett.Org. Chem. 1996, 61, 4439–4449.
Citation Manager style files: Authors are highly
encouraged to use the citation manager programs for citing and
formatting the references. Authors may use free Mendelay, Zotero, Paper 2
or Endnote program. If you are using any of these citation manager
program for Bibliography (References and Notes), then you can download
citation style file for journal (common for ISP journals):
click to download and then open in respective program (the user can
see the respective program user guide on how to use the style file).
Authors need to submit all manuscripts through journal website.
Register by following link ‘Register’ above (make sure to mark checked
the options Author and reviewer while registering for journal). On
login, you will find ‘new submission’ link in your panel page.
For review purpose, author can submit the manuscript as outlined
above. However, Authors are advised to prepare their manuscript
according to journal article template (provided below) as it progress
towards acceptance. On acceptance of manuscript, authors must need to
supply their manuscript in Article template (if they have not already
submitted in template). If you face difficulty in preparing manuscript
according to template, then you can forward your manuscript (place all
figures with caption in the end of file) to Copyeditor/Support
department ( email@example.com )
On acceptance of manuscript, Authors are required to submit revised
manuscript in journal articles template (If authors wish, they are free
to submit their manuscript in journal article template while submitting
download the template (as per the MS Word version that you have on
your computer), double click the file to open and then prepare your
article and save it with your own name.
Login and submit the manuscript online (submission by email are not accepted). Only online submissions are accepted now.
Authors are advised to contact Support, Biomed Frontiers (email: pubs @ thesciencein.org ) if there is any problem in registration or submission.
Declaration of Conflict of Interest
Authors should mention any conflict of interest in the work submitted to Biomedical Frontiers. The statement about conflict of interest may be mentioned in the ‘Letter to editor’ or placed in the manuscript after acknowledgement section.
Ethical Uses Declaration:
If the manuscript report the experimentation on animals (including
clinical trials on human beings), then declaration about ethical way
handling of animals and about keeping the complete privacy of human
identity (in case of clinical trials) must be mentioned in the
Helsinki Declaration (contents from NIH-NLM): When reporting
experiments on human subjects, authors should indicate whether the
procedures followed were in accordance with the ethical standards of the
responsible committee on human experimentation (institutional and
national) and with the Helsinki Declaration of 1975, as revised in 2000
(5). If doubt exists whether the research was conducted in accordance
with the Helsinki Declaration, the authors must explain the rationale
for their approach, and demonstrate that the institutional review body
explicitly approved the doubtful aspects of the study. When reporting
experiments on animals, authors should be asked to indicate whether the
institutional and national guide for the care and use of laboratory
animals was followed.
Submit manuscript on journal editorial processing site at
Coumarin, triazoles and thiazolidinones are one of the most preferred and high valued scaffolds frequently used in medicinal chemistry. The synthesis of newly designed coumarin based triazolyl-thiazolidinones was performed and new compounds were obtained in good yields. The listed compounds were evaluated for their apoptotic activity and determined the minimal inhibitory concentrations for each of the compound on SCC-4 cells using MTT viability test. Furthermore, apoptotic inducer activity was assayed by detecting the expression of caspase-3, a key apoptotic enzyme.
Cite as: FNU, P., Sinha, N., Kumar, S., FNU, A., Kumar, S., Kumar, P., Pandey, A., Sharma, P., Aggarwal, V., FNU, P., Mothsra, P., Singh, B., Singh, R., & Kumar, Y. (2019). Synthesis of coumarin based triazolyl thiazolidinones and their apoptotic inducer activity against caspase-3. Chemical Biology Letters, 6(2), 30-38.